Literature DB >> 28108313

The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.

Daniela Schilling1, Carmen Garrido2, Stephanie E Combs3, Gabriele Multhoff3.   

Abstract

The inhibition of heat shock protein 90 (Hsp90) is a promising strategy to increase the radiosensitivity of tumor cells. However, Hsp90 inhibition induces the expression of Hsp70 which is a prominent cytoprotective protein. Therefore, dual targeting of Hsp70 and Hsp90 might be beneficial to increase the radiosensitivity of tumor cells. Hsp70 inhibiting peptide aptamers have been shown to increase the sensitivity of tumor cells to apoptosis induced by different anticancer drugs. Herein, we studied the radiosensitizing activity of the Hsp70 inhibiting peptide aptamer A17 in combination with the Hsp90 inhibitor NVP-AUY922. Whereas A17 significantly increased apoptosis induction by NVP-AUY922 it did not significantly affect the radiosensitivity of human lung and breast cancer cells. However, Hsp70 inhibition by the aptamer A17 potentiated the radiosensitizing effects of the Hsp90 inhibitor NVP-AUY922. Mechanistically we speculate that an increased number of DNA double strand breaks and an enhanced G2/M arrest might be responsible for the increased radiosensitization in A17 expressing tumor cells. Therefore, the simultaneous inhibition of Hsp90 and Hsp70 combined with radiotherapy might provide a promising anti-cancer strategy.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aptamer; Heat shock protein 70 (Hsp70); Heat shock protein 90 (Hsp90); NVP-AUY922; Radiosensitization

Mesh:

Substances:

Year:  2017        PMID: 28108313     DOI: 10.1016/j.canlet.2017.01.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  8 in total

1.  Thermal inkjet bioprinting triggers the activation of the VEGF pathway in human microvascular endothelial cells in vitro.

Authors:  Luis H Solis; Yoshira Ayala; Susana Portillo; Armando Varela-Ramirez; Renato Aguilera; Thomas Boland
Journal:  Biofabrication       Date:  2019-07-09       Impact factor: 9.954

Review 2.  Strategies to Enhance Radiosensitivity to Heavy Ion Radiation Therapy.

Authors:  Younghyun Lee; Ryuichi Okayasu
Journal:  Int J Part Ther       Date:  2018-09-21

3.  Upregulated Heat Shock Proteins After Hyperthermic Chemotherapy Point to Induced Cell Survival Mechanisms in Affected Tumor Cells From Peritoneal Carcinomatosis.

Authors:  Tanja Grimmig; Eva-Maria Moll; Kerstin Kloos; Rebecca Thumm; Romana Moench; Simone Callies; Jennifer Kreckel; Malte Vetterlein; Joerg Pelz; Buelent Polat; Sudipta Tripathi; Roberta Rehder; Carmen M Ribas; Anil Chandraker; Christoph-T Germer; Ana Maria Waaga-Gasser; Martin Gasser
Journal:  Cancer Growth Metastasis       Date:  2017-09-18

4.  Antifungal activity of an artificial peptide aptamer SNP-D4 against Fusarium oxysporum.

Authors:  Junjun Huang; Dan Wang; Hong Li; Yanqiong Tang; Xiang Ma; Hongqian Tang; Min Lin; Zhu Liu
Journal:  PeerJ       Date:  2022-02-22       Impact factor: 2.984

Review 5.  Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy.

Authors:  Sihan Du; Ying Liu; Yuan Yuan; Yuran Wang; Yanfang Chen; Shuai Wang; Yuhua Chi
Journal:  Front Cell Dev Biol       Date:  2022-08-10

Review 6.  Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy.

Authors:  Jie Yin; Wenkai Ren; Xingguo Huang; Jinping Deng; Tiejun Li; Yulong Yin
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

Review 7.  Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.

Authors:  Maxim Shevtsov; Gabriele Multhoff; Elena Mikhaylova; Atsushi Shibata; Irina Guzhova; Boris Margulis
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

Review 8.  Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications.

Authors:  Baozhang Guan; Xingwang Zhang
Journal:  Int J Nanomedicine       Date:  2020-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.